Latest Breaking News On - Siteman cancer center biostatistics shared resource - Page 1 : comparemela.com

Giving chemotherapy in the morning can extend survival of glioblastoma patients An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment to the current standard treatment -; giving chemotherapy in the morning rather than the evening -; could add a few months to patients survival. The study appears online in the journal Neuro-Oncology Advances. Average overall survival for all patients in the study was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically

Annar damatoJoshuab rubinJianl campianErikd herzogEmily hendersonSchool of medicineSiteman cancer center biostatistics shared resourceSiteman cancer center at barnesDivision of biology biomedical sciencesWashington university school of medicineArts sciencesDivision of public health sciencesBrain tumor center at sitemanWashington university in stWashington universityWashington university school